Seeking Alpha
26 Sept 2026, 12:48 UTC · 2h ago
Verdict
Headline leans bullish. We score ALKS +0.80 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
Alkermes' Lumryz showed positive Phase 3 results for the treatment of idiopathic hypersomnia (IH).
Priced inanalysis piece by contributing analyst
So whatExpansion into IH creates a second distinct revenue stream beyond narcolepsy, likely boosting 2027E EBITDA estimates.
More positive than 93% of claims this week
Alkermes will owe Jazz Pharmaceuticals a 10% royalty on non-narcolepsy Lumryz sales starting after March 2028.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis piece by contributing analyst
So whatThis royalty creates a margin headwind for the IH indication that will trigger in FY2028.
More negative than 77% of claims this week
The author values Alkermes at $57 per share based on 35x 2027E EBITDA.
Neworiginal finding this article establishes
So whatThis target provides a specific valuation benchmark for the stock's upside based on the analyst's projected 2027 earnings.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Positive Phase 3 results for LUMRYZ's expansion into idiopathic hypersomnia are expected to drive growth and revenue.
More positive than 61% of ticker scores this week
The company is set to receive a 10% royalty on non-narcolepsy LUMRYZ sales starting in March 2028.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
7h ago
—
ALKS hasn't traded since this ran. Last close $40.85 (Sep 25); the reaction starts at the next open.
ALKS chart →
